Newsletter
News and Events
Home
Company
Pipeline
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
© relief therapeutics 2024
Latest News
Stay up to date on Relief activities
Corporate News
Archive
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
8 May 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics has published its Annual Report
30 April 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
27 March 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
22 March 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
28 February 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
5 December 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces CEO Transition
22 November 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
10 October 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
15 September 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
30 August 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Company
Pipeline
Investor Relations
News and Events
© Relief Therapeutics